肝細胞癌(HCC)患者におけるレンバチニブの肝機能への早期影響とその予後的意義:単一施設後ろ向き研究
Pei Wang1, Shuheng Liu2, Xiaoxia Lu1
1Department of Digestive Medicine, Wuwei People's Hospital, Wuwei City, Gansu Province, 733000, People's Republic of China.
Objective:
Lenvatinib shows efficacy for tumor response and survival in patients with advanced hepatocellular carcinoma (HCC). We aim to assess the effect of lenvatinib on liver function.
Methods:
This single-center retrospective cohort study included 40 patients with advanced HCC who received ≥ 2 months of lenvatinib treatment from January 2020 to January 2024 and had at least one efficacy and safety assessment.
Results:
The ALBI score showed a slight but significant increase of 0.112 points, from -2.517 at baseline to -2.405 following 2-month of treatment (P < 0.05). With a median follow-up of 18.5 months, the median overall survival was 22.8 months (95% CI: 16.3-29.3), and the median progression-free survival was 12.7 months (95% CI: 9.1-16.3). Both COX regression and Kaplan-Meier analyses indicated that impaired baseline liver function was associated with adverse clinical outcomes. Additionally, treatment response emerged as an independent prognostic factor.
Conclusions:
The baseline ALBI score serves as a key prognostic marker, highlighting the necessity for meticulous monitoring of hepatic function, particularly in patients with compromised baseline liver reserve.
Limitations:
The limitations of this study include its retrospective design and the potential for selection bias arising from the requirement for at least 2 months of treatment.
関連する概念動画
Significance of Center of Mass
Statistical Significance
The Significance of Membrane Transport
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Significance Testing: Overview


